Hande Liv Nesse, Thunhaug Hilde, Ludviksen Judith, Hovland Anders, Lappegård Knut Tore
UiT The Arctic University of Norway, Tromsø, Norway.
Department of Medicine, Nordland Hospital, Bodø, Norway.
Scand J Clin Lab Invest. 2023 May;83(3):152-159. doi: 10.1080/00365513.2023.2178499. Epub 2023 Mar 31.
Individuals with familial hypercholesterolemia (FH) have increased cardiovascular risk despite lipid-lowering therapy, and additional therapy is warranted. Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplements have demonstrated an effect on cardiovascular endpoints in some clinical trials. Platelet-modifying and anti-inflammatory properties are among the proposed beneficial effects of n-3 PUFA. We investigated the effect of a high-dose n-3 PUFA supplement on platelet function and inflammatory markers in FH subjects. We performed a randomized, double-blind trial with a crossover design. Inclusion criteria were genetically verified heterozygous FH, stable disease, statin treatment >12 months, and age 18-75 years. Trial participants were allocated to two treatment periods in random order. The treatment periods (three months each) were separated by a three-month washout period. N-3 PUFA (1840 mg eicosapentaenoic acid and 1520 mg docosahexaenoic acid) and placebo (olive oil) were administered in four capsules daily. Endpoints were platelet function and inflammatory markers, assessed by platelet function analyzer, soluble markers P-selectin, vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM), 27 cytokines, and hematological parameters. Thirty-four heterozygous FH individuals completed the trial. No treatment effect ( = 0.93) from n-3 PUFA on the platelet function analyzer was found (2 s, 95% CI [-13, 6]). In our FH population, n-3 PUFA did not influence the levels of P-selectin (-2.0, 95% CI [-5.0, 2.0], = 0.41), VCAM (0, 95% CI [-14.2, 14.2], > 0.99), ICAM (-27.0, 95% CI [-70.1, 16.5]; = 0.21), cytokine levels, or hematological parameters. In statin-treated FH individuals, high dose n-3 PUFA supplement did not affect platelet function and inflammatory markers. EUDRACTNR 2012-000505-68; ClinicalTrials.gov NCT01813006HighlightsTrial studying the effect of omega-3 fatty acids supplements in familial hypercholesterolemia.High-dose omega-3 fatty acids supplements had no impact on platelet function.Cytokine levels were unchanged after three months of omega-3 fatty acid supplementation.No effect of omega-3 fatty acids on C-reactive protein was observed.
患有家族性高胆固醇血症(FH)的个体,即便接受了降脂治疗,其心血管疾病风险仍会增加,因此需要额外的治疗。在一些临床试验中,ω-3多不饱和脂肪酸(n-3 PUFA)补充剂已显示出对心血管终点指标有影响。血小板调节和抗炎特性是n-3 PUFA所具有的一些潜在有益作用。我们研究了高剂量n-3 PUFA补充剂对FH患者血小板功能和炎症标志物的影响。我们进行了一项采用交叉设计的随机双盲试验。纳入标准为经基因验证的杂合子FH、病情稳定、他汀类药物治疗超过12个月且年龄在18至75岁之间。试验参与者被随机分配到两个治疗期。治疗期(各三个月)之间有一个为期三个月的洗脱期。n-3 PUFA(1840毫克二十碳五烯酸和1520毫克二十二碳六烯酸)和安慰剂(橄榄油)每天分四粒胶囊服用。终点指标为血小板功能和炎症标志物,通过血小板功能分析仪、可溶性标志物P-选择素、血管细胞黏附分子(VCAM)和细胞间黏附分子(ICAM)、27种细胞因子以及血液学参数进行评估。34名杂合子FH个体完成了试验。未发现n-3 PUFA对血小板功能分析仪有治疗效果(=0.93)(2秒,95%置信区间[-13, 6])。在我们的FH人群中,n-3 PUFA未影响P-选择素水平(-2.0,95%置信区间[-5.0, 2.0],=0.41)、VCAM水平(0,95%置信区间[-14.2, 14.2],>0.99)、ICAM水平(-27.0,95%置信区间[-70.1, 16.5];=0.21)、细胞因子水平或血液学参数。在接受他汀类药物治疗的FH个体中,高剂量n-3 PUFA补充剂未影响血小板功能和炎症标志物。欧盟临床试验注册号2012 - 000505 - 68;美国国立医学图书馆临床试验注册号NCT01813006要点研究ω-3脂肪酸补充剂对家族性高胆固醇血症影响的试验。高剂量ω-3脂肪酸补充剂对血小板功能无影响。补充ω-3脂肪酸三个月后细胞因子水平未改变。未观察到ω-3脂肪酸对C反应蛋白有影响。